Back to top

crispr: Archive

Kevin Cook

Bull of the Day: CRISPR Therapeutics (CRSP)

FDA approval for revolutionary Sickle Cell Disease gene-editing treatment promises a bright future

CRSPNegative Net Change VRTXPositive Net Change EDITNegative Net Change

Zacks Equity Research

CRISPR (CRSP) to Focus on Next-Generation CAR T Pipeline

Based on early data from ongoing clinical studies, CRISPR (CRSP) has decided to focus on the development of its next-generation CAR T pipeline and discontinue its first-generation CAR T candidates.

NVOPositive Net Change VRTXPositive Net Change CTMXNegative Net Change CRSPNegative Net Change